Middle East & Africa Infectious Disease Therapeutics Market Forecast to 2030 - Regional Analysis - by Drug Class (Anti-viral, Anti-Bacterial, Anti-Fungal, and Others), Indication (HIV, Hepatitis, Tuberculosis, Influenza, HPV, and Others), Route of Administration (Oral, Parenteral, Topical, and Others), and Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Others)
The Middle East & Africa infectious disease therapeutics market was valued at US$ 5,722.81 million in 2022 and is expected to reach US$ 7,237.61 million by 2030; it is estimated to register a CAGR ... もっと見る
※当ページの内容はウェブ更新時の情報です。
SummaryThe Middle East & Africa infectious disease therapeutics market was valued at US$ 5,722.81 million in 2022 and is expected to reach US$ 7,237.61 million by 2030; it is estimated to register a CAGR of 3.0% from 2022 to 2030.Rising Prevalence of Infectious Disease Fuels Middle East & Africa Infectious Disease Therapeutics Market Infectious diseases are caused by viruses, parasites, bacteria, fungi, toxic products, and other infectious agents. HIV is a major public health issue across the world. According to The Joint United Nations Programme on HIV/AIDS (UNAIDS), in 2020, ~ 37.7 million people had HIV. Out of these, 36 million were adults, and 1.7 million were children aged 0-14 years. Also, more than half (53%) were girls and women. Moreover, 1.5 million new HIV cases were reported in 2020 globally. Similarly, hepatitis is an infection of the liver caused by a viral infection. The main types of hepatitis viruses are A, B, C, D, and E. According to the World Health Organization (WHO), globally, ~ 58 million people are suffering from chronic hepatitis C virus infection, and every year, ~1.5 million new infections occur. According to WHO, tuberculosis (TB) is the 13th top cause of death globally and the second leading infectious disease after COVID-19. In 2020, 1.5 million deaths were caused by TB (including 214,000 people affected by HIV). Furthermore, 10 million people had TB globally in 2020, including 1.1 million children, 3.3 million women, and 5.6 million men. Moreover, hospital-acquired infections or healthcare-associated infections (HAIs) have a high morbidity and mortality rate. Also, the expenditure on the healthcare system is huge every year. Therefore, the rising prevalence of infectious diseases across the globe drives the growth of the infectious disease therapeutics market. Middle East & Africa Infectious Disease Therapeutics Market Overview The infectious disease therapeutics market in the Middle East & Africa includes a country-level analysis of the UAE, Saudi Arabia, South Africa, and the Rest of Middle East & Africa. The market growth can be attributed to the increasing prevalence of chronic viral diseases and growing research studies across the region. Moreover, the emergence of advanced healthcare facilities is likely to propel market growth during the forecast period. Saudi Arabia is among the fastest-growing regions in the Middle East & Africa, driven by a huge population base and the increasing prevalence of infectious diseases. Tuberculosis in Saudi Arabia is spread through migrant workers and pilgrims. According to the World Data Atlas, the incidence rate of tuberculosis in Saudi Arabia gradually fell from 17 cases per 100,000 people in 2002 to 8 cases per 100,000 people in 2021. Further, K. pneumoniae, a hospital-acquired infection of the urinary tract, bloodstream, and respiratory tract, is very challenging to control in Saudi Arabia. Influenza and pneumonia deaths reached 4.58% of total deaths in the country, according to WHO. To address the growing influenza cases, the Public Health Laboratory in Saudi Arabia fulfilled all the requirements by WHO to be recognized as a national influenza center for Saudi Arabia. The center plays a critical role in rapidly detecting and monitoring infectious diseases. NIAID is significantly involved in research on infectious viral diseases in the region, including MERS-CoV. MERS-CoV, a newly identified coronavirus, has spread to at least nine countries in the region. NIAID is significantly involved in research on infectious viral diseases in the region. Similarly, product launches in the region are increasing and are positively impacting patients' quality of life. Thus, the growing number of viral diseases and product launches is anticipated to propel the growth of infectious disease therapeutics in the country. Middle East & Africa Infectious Disease Therapeutics Market Revenue and Forecast to 2030 (US$ Million) Middle East & Africa Infectious Disease Therapeutics Market Segmentation The Middle East & Africa infectious disease therapeutics market is categorized into drug class, indication, route of administration, distribution channel, and country. Based on drug class, the Middle East & Africa infectious disease therapeutics market is segmented into anti-viral, anti-bacterial, anti-fungal, and others. The anti-viral segment held the largest market share in 2022. In terms of indication, the Middle East & Africa infectious disease therapeutics market is segmented into HIV, hepatitis, tuberculosis, influenza, HPV, and others. The HIV held the largest market share in 2022. Based on route of administration, the Middle East & Africa infectious disease therapeutics market is segmented into oral, parenteral, topical, and others. The oral segment held the largest market share in 2022. In terms of distribution channel, the Middle East & Africa infectious disease therapeutics market is segmented into hospital pharmacies, retail pharmacies, and others. The hospital pharmacies held the largest market share in 2022. By country, the Middle East & Africa infectious disease therapeutics market is segmented into Saudi Arabia, South Africa, the UAE, and the Rest of Middle East & Africa. Saudi Arabia dominated the Middle East & Africa infectious disease therapeutics market share in 2022. AbbVie Inc, Astellas Pharma Inc, Bayer AG, F. Hoffmann-La Roche Ltd, Gilead Sciences Inc, GSK Plc , Merck & Co Inc, and Pfizer Inc are some of the leading companies operating in the Middle East & Africa infectious disease therapeutics market. Table of ContentsTABLE OF CONTENTS1. Introduction 1.1 The Insight Partners Research Report Guidance 1.2 Market Segmentation 2. Executive Summary 2.1 Key Insights 3. Research Methodology 3.1 Coverage 3.2 Secondary Research 3.3 Primary Research 4. Middle East & Africa Infectious Disease Therapeutics Market - Key Market Dynamics 4.1 Middle East & Africa Infectious Disease Therapeutics Market - Key Market Dynamics 4.2 Market Drivers 4.2.1 Rising Prevalence of Infectious Disease 4.2.2 Increasing Focus on Funding and R&D in Infectious Disease Therapeutics 4.3 Market Restraints 4.3.1 Emergence of Anti-infective Drugs Resistance and Associated Side Effects 4.4 Market Opportunities 4.4.1 Escalating Threat of Antibiotic Resistance 4.5 Future Trends 4.5.1 Rising Number of Product Approvals and Launches 4.6 Impact of Drivers and Restraints: 5. Infectious Disease Therapeutics Market - Middle East & Africa Market Analysis 5.1 Middle East & Africa Infectious Disease Therapeutics Market Revenue (US$ Million), 2022-2030 6. Middle East & Africa Infectious Disease Therapeutics Market Analysis - by Drug Class 6.1 Overview 6.2 Anti-Viral 6.2.1 Overview 6.2.2 Anti-viral: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) 6.3 Anti-bacterial 6.3.1 Overview 6.3.2 Anti-bacterial: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) 6.4 Anti-fungal 6.4.1 Overview 6.4.2 Anti-fungal: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) 6.5 Others 6.5.1 Overview 6.5.2 Others: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) 7. Middle East & Africa Infectious Disease Therapeutics Market Analysis - by Indication 7.1 Overview 7.2 HIV 7.2.1 Overview 7.2.2 HIV: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) 7.3 Hepatitis 7.3.1 Overview 7.3.2 Hepatitis: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) 7.4 Tuberculosis 7.4.1 Overview 7.4.2 Tuberculosis: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) 7.5 Influenza 7.5.1 Overview 7.5.2 Influenza: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) 7.6 HPV 7.6.1 Overview 7.6.2 HPV: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) 7.7 Others 7.7.1 Overview 7.7.2 Others: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) 8. Middle East & Africa Infectious Disease Therapeutics Market Analysis - by Route of Administration 8.1 Overview 8.2 Oral 8.2.1 Overview 8.2.2 Oral: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) 8.3 Parenteral 8.3.1 Overview 8.3.2 Parenteral: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) 8.4 Topical 8.4.1 Overview 8.4.2 Topical: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) 8.5 Others 8.5.1 Overview 8.5.2 Others: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) 9. Middle East & Africa Infectious Disease Therapeutics Market Analysis - by Distribution Channel 9.1 Overview 9.2 Hospital Pharmacies 9.2.1 Overview 9.2.2 Hospital Pharmacies: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) 9.3 Retail Pharmacies 9.3.1 Overview 9.3.2 Retail Pharmacies: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) 9.4 Others 9.4.1 Overview 9.4.2 Others: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) 10. Middle East & Africa Infectious Disease Therapeutics Market - Country Analysis 10.1 Middle East & Africa Infectious Disease Therapeutics Market 10.1.1 Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast Analysis - by Country 10.1.1.1 Middle East & Africa: Infectious Disease Therapeutics Market - Revenue and Forecast Analysis - by Country 10.1.1.2 South Africa: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) 10.1.1.2.1 Overview 10.1.1.3 Saudi Arabia: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) 10.1.1.3.1 Saudi Arabia: Infectious Disease Therapeutics Market Breakdown, by Drug Class 10.1.1.3.2 Saudi Arabia: Infectious Disease Therapeutics Market Breakdown, by Indication 10.1.1.3.3 Saudi Arabia: Infectious Disease Therapeutics Market Breakdown, by Route of Administration 10.1.1.3.4 Saudi Arabia: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel 10.1.1.4 South Africa: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) 10.1.1.4.1 Overview 10.1.1.5 South Africa: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) 10.1.1.5.1 South Africa: Infectious Disease Therapeutics Market Breakdown, by Drug Class 10.1.1.5.2 South Africa: Infectious Disease Therapeutics Market Breakdown, by Indication 10.1.1.5.3 South Africa: Infectious Disease Therapeutics Market Breakdown, by Route of Administration 10.1.1.5.4 South Africa: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel 10.1.1.6 United Arab Emirates: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) 10.1.1.6.1 Overview 10.1.1.7 United Arab Emirates: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) 10.1.1.7.1 United Arab Emirates: Infectious Disease Therapeutics Market Breakdown, by Drug Class 10.1.1.7.2 United Arab Emirates: Infectious Disease Therapeutics Market Breakdown, by Indication 10.1.1.7.3 United Arab Emirates: Infectious Disease Therapeutics Market Breakdown, by Route of Administration 10.1.1.7.4 United Arab Emirates: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel 10.1.1.8 Rest of Middle East & Africa: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) 10.1.1.8.1 Overview 10.1.1.9 Rest of Middle East & Africa: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) 10.1.1.9.1 Rest of Middle East & Africa: Infectious Disease Therapeutics Market Breakdown, by Drug Class 10.1.1.9.2 Rest of Middle East & Africa: Infectious Disease Therapeutics Market Breakdown, by Indication 10.1.1.9.3 Rest of Middle East & Africa: Infectious Disease Therapeutics Market Breakdown, by Route of Administration 10.1.1.9.4 Rest of Middle East & Africa: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel 11. Infectious Disease Therapeutics Market-Industry Landscape 11.1 Overview 11.2 Growth Strategies in the Infectious Disease Therapeutics Market 11.3 Inorganic Growth Strategies 11.3.1 Overview 11.4 Organic Growth Strategies 11.4.1 Overview 12. Company Profiles 12.1 Pfizer Inc 12.1.1 Key Facts 12.1.2 Business Description 12.1.3 Products and Services 12.1.4 Financial Overview 12.1.5 SWOT Analysis 12.1.6 Key Developments 12.2 Gilead Sciences Inc 12.2.1 Key Facts 12.2.2 Business Description 12.2.3 Products and Services 12.2.4 Financial Overview 12.2.5 SWOT Analysis 12.2.6 Key Developments 12.3 F. Hoffmann-La Roche Ltd 12.3.1 Key Facts 12.3.2 Business Description 12.3.3 Products and Services 12.3.4 Financial Overview 12.3.5 SWOT Analysis 12.3.6 Key Developments 12.4 Bayer AG 12.4.1 Key Facts 12.4.2 Business Description 12.4.3 Products and Services 12.4.4 Financial Overview 12.4.5 SWOT Analysis 12.4.6 Key Developments 12.5 GSK Plc 12.5.1 Key Facts 12.5.2 Business Description 12.5.3 Products and Services 12.5.4 Financial Overview 12.5.5 SWOT Analysis 12.5.6 Key Developments 12.6 AbbVie Inc 12.6.1 Key Facts 12.6.2 Business Description 12.6.3 Products and Services 12.6.4 Financial Overview 12.6.5 SWOT Analysis 12.6.6 Key Developments 12.7 Merck & Co Inc 12.7.1 Key Facts 12.7.2 Business Description 12.7.3 Products and Services 12.7.4 Financial Overview 12.7.5 SWOT Analysis 12.7.6 Key Developments 12.8 Astellas Pharma Inc 12.8.1 Key Facts 12.8.2 Business Description 12.8.3 Products and Services 12.8.4 Financial Overview 12.8.5 SWOT Analysis 12.8.6 Key Developments 13. Appendix 13.1 About The Insight Partners
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野(通信回線)の最新刊レポート
The Insight Partners 社の最新刊レポート
本レポートと同じKEY WORD(administration)の最新刊レポート
よくあるご質問The Insight Partners社はどのような調査会社ですか?The Insight Partnersはインドに本社を置く調査会社です。経験豊富な専門家チームを通じて、お客様に最適な調査と分析を提供することに専念しています。幅広い分野をカバーしていますがヘルスケ... もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
詳細検索
2024/10/08 10:26 148.90 円 163.91 円 197.75 円 |